In vitro and in vivo pharmacological models to assess demyelination and remyelination

Neuropsychopharmacology

Volumn 34, Issue 1, 2009, Pages 55-73

  Merrill, Jean E ^a  

^a SANOFI   (France)

Author keywords

Cuprizone model; Drug discovery; Experimental autoimmune encephaloneyelitis; Multiple sclerosis; Oligodendrocyte; Remyelination

Indexed keywords

CELL CULTURE; DEMYELINATION; DISEASE MODEL; DRUG RESEARCH; DRUG SCREENING; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; REMYELINIZATION; REVIEW;

ANIMALS; CELL LINE; CELLS, CULTURED; DEMYELINATING DISEASES; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; MULTIPLE SCLEROSIS;

EID: 57649116340     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2008.145     Document Type: Review

References (151)

1. Adamo AM, Paez PM, Escobar Cabrera OE, Wolfson M, Franco PG, Pasquini JM et al (2006). Remyelination after cuprizone-induced demyelination in the rat is stimulated by apotransferrin. Exp Neurol 198: 519-529.
2. Anderson SA, Shukalial-Quandt J, Jordan EK, Arbab AS, Martin R, McFarland H et al (2004). Magnetic resonance imaging of labeled T-cells in a mouse model of multiple sclerosis. Ann Neurol 55: 654-659.
3. Armstrong RC, Dorn HH, Kufta CV, Friedman E, Dubois-Dalcq ME (1992). Preoligodendrocytes from adult human CNS. J Neurosci 12: 1538-1547.
4. Arnon R (1981). Experimental allergic encephalomyelitis - susceptibility and suppression. Immunol Rev 55: 5-30.
5. Atkinson S, Li Y-Q, Wong SC (2003). Changes in oligodendrocytes and myelin gene expression after radiation in the rodent spinal cord. Int J Radiat Oncol Biol Phys 57: 1093-1100.
6. Barres BA, Hart IK, Coles HSR, Burne JF, Voyvodic JT, Richardson WD et al (1992). Cell death and control of cell survival in the oligodendrocyte lineage. Cell 70: 31-46.
7. Bechtold DA, Kapoor R, Smith KJ (2004). Axonal protection using flecainide in experimental autoimmune encephalomyelitis. Ann Neurol 55: 607-616.
8. Beeton C, Wulff H, Barbaria J, Clot-Faybesse O, Pennington M, Bernard D et al (2001). Selective blockade of T lymphocyte K+ channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc Natl Acad Sci USA 98: 13942-13947.
9. Benveniste EN, Merrill JE (1986). Stimulation of oligodendroglial proliferation and maturation by interleukin-2. Nature 321: 610-613.
10. Berger C, Hiestand P, Kindler-Baumann D, Rudin M, Rausch M (2006). Analysis of lesion development during acute inflammation and remission in the rat model of experimental autoimmune encephalomyelitis by visualization of macrophage infiltration, demyelination, and blood-brain barrier damage. NMR Biomed 19: 101-107.
11. Bernard CCA (1976). Experimental autoimmune encephalomyelitis in mice: genetic control of susceptibility. J Immunogenet 3: 263-274.
12. Blakemore WF, Franklin RJM (1991). Transplantation of glial cells into the CNS. Trends Neurosci 14: 323-327.
13. Blanchard AP, Friend SH (1999). Cheap DNA arrays-it's not all smoke and mirrors. Nat Biotechnol 17: 953.
14. Bo L, Dawson TM, Wesselingh S, Mork S, Choi S, King PA et al (1994). Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann Neurol 36: 778-786.
15. Boullerne AI, Benjamins JA (2006). Nitric oxide synthase expression and nitric oxide toxicity in oligodendrocytes. Antiox Redox Signal 8: 967-980.
16. Brochet B, Deloire MSA, Touil T, Anne O, Caille JM, Dopusset V et al (2006). Early macrophage MRI of inflammatory lesions predicts lesion severity and disease development in relapsing EAE. Neuroimage 32: 266-274.
17. Brogi A, Strazza M, Melli M, Constantino-Ceccarini E (1997). Induction of intracellular ceramide by interleukin-1B in oligodendrocytes. J Cell Biochem 66: 532-541.
18. Brok HPM, Bauer J, Jonker M, Blezer E, Amor S, Bontrop RE et al (2001). Non-human primate models of multiple sclerosis. Immunol Rev 183: 173-185.
19. Brosnan CF, Battistini L, Raine CS, Dickson DW, Casadevall A, Lee SC (1994). Reactive nitrogen intermediates in human neuropathology: an overview. Dev Neurosci 16: 152-161.
20. Butzkueven H, Zhang J-G, Soilu-Hanninen M, Hochrein H, Chionh F, Shipham KA et al (2002). LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival. Nat Med 8: 613-619.
21. Casaccia-Bonnefil P (2000). Cell death in the oligodendrocyte lineage: a molecular perspective of life/death decisions in development and disease. Glia 29: 124-135.
22. Casaccia-Bonnefil P, Aibel L, Chao MV (1996). Central glial and neuronal populations display differential sensitivity to ceramide-dependent cell death. J Neurosci Res 43: 382-389.
23. Chakraborty G, Ziemba S, Drivas A, Ledeen RW (1997). Myelin contains neutral sphingomyelinase activity that is stimulated by tumor necrosis factor-α. J Neurosci Res 50: 466-476.
24. Charles P, Hernandez MP, Stankoff B, Aigrot MS, Colin C, Rougon G et al (2000). Negative regulation of central nervous system myelination by polysialated-neural cell adhesion molecule. Proc Natl Acad Sci USA 97: 7585-7590.
25. Coman I, Barbin G, Charles P, Zalc B, Lubetzki C (2005). Axonal signals in the central nervous system myelination, demyelination, and remyelination. J Neurol Sci 233: 67-71.
26. Copelman CA, Cuzner ML, Groome N, Diemel LT (2000). Temporal analysis of growth factor mRNA expression in myelinating rat brain aggregrate cultures: increments in CNTF, FGF-2, IGF-1, and PDGF-AA mRNA are induced by antibody-mediated demyelination. Glia 30: 342-351.
27. Dal Canto MC, Lipton HL (1976). Primary demyelination in Theiler's virus infection. Lab Invest 33: 626-637.
28. Dalal M, Kim S, Voskuhl RR (1997). Testosterone therapy ameliorates experimental autoimmune encephalomyelitis and induces a T helper 2 bias in the autoantigen-specific T lymphocyte response. J Immunol 159: 3-6.
29. Davis MD, Clemens JJ, Macdonald TL, Lynch KR (2005). Sphingosine 1-phosphate analogs as receptor antagonists. J Biol Chem 280: 9833-9841.
30. Demerens C, Stankoff B, Logak M, Anglade P, Allinquant B, Couraud F et al (1996). Induction of myelination in the central nervous system by electrical activity. Proc Natl Acad Sci USA 93: 9887-9892.
31. Diem R, Sattler MB, Merkler D, Demmer I, Maier K, Stadelmann C et al (2005). Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis. Brain 128: 375-385.
32. Dousset V, Brochet B, Vital A, Gross C, Benazzouz A, Boullerne A et al (1995). Lysolecithin-induced demyelination in primates: preliminary in vivo study with MR and magnetization transfer. Am J Neuroradiol 16: 225-231.
33. Eccleston PA, Silberberg DH (1984). The differentiation of oligodendrocytes in serum-free hormone-supplemented medium. Dev Brain Res 16: 1-9.
34. Fernandez M, Giuliani A, Pirondi S, D'Intino G, Giardino L, Aloe L et al (2004). Thyroid hormone administration enhances remyelination in chronic demyelinating inflammatory disease. Proc Natl Acad Sci USA 101: 16363-16368.
35. Feurer C, Prentice DE, Cammisuli S (1985). Chronic relapsing experimental allergic encephalomyelitis in the Lewis rat. J Neuroimmunol 10: 159-166.
36. Floris A, Blezer ELA, Schreibelt G, Dopp E, van der Pol SMA, Schadee-Eestermans IL et al (2004). Blood-brain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis: a quantitative MRI study. Brain 127: 616-627.
37. Foster LM, Phan T, Verity AN, Bredesen D, Campagnoni AT (1993). Generation and analysis of normal and shiverer temperature-sensitive immortalized cell lines exhibiting phenotypic characteristics of oligodendrocytes at several stages of differentiation. Dev Neurosci 15: 100-109.
38. Fox RI, Herrmann ML, Frangou CG, Wahl GM, Morris RE, Strand V et al (1999). Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol 93: 198-208.
39. Franco-Pons N, Torrente M, Colomina MT, Vilella E (2007). Behavioral deficits in the cuprizone-induced murine model of demyelination/remyelination. Toxicol Lett 169: 205-213.
40. Franklin RJM (2002). Why does remyelination fail in multiple sclerosis? Nat Rev 3: 705-714.
41. Franklin RJM, Blakemore WF (1995). Glial-cell transplantation and plasticity in the O-2A lineage-implications for CNS repair. Trends Neurosci 18: 151-156.
42. Fujiyoshi K, Tamada M, Nakamura M, Yamane J, Katoh H, Kitamure K et al (2007). In vivo tracing of neural tracts in the intact and injured spinal cord of marmosets by diffusion tensor tractography. J Neurosci 27: 11991-11998.
43. Gallo V, Zhou JM, McBain CJ, Wright P, Knutson PL, Armstrong RC (1996). Oligodendrocyte progenitor cell proliferation and lineage progression are regulated by glutamate receptor-mediated K+ channel block. J Neurosci 16: 2659-2670.
44. Genain GP, Hauser SL (2001). Experimental allergic encephalomyelitis in the new world monkey Callithrix jacchus. Immunol Rev 183: 159-172.
45. Gilson J, Blakemore WF (1993). Failure of remyelination in areas of demyelination produced in the spinal cord of old rats. Neuropathol Appl Neurobiol 19: 173-181.
46. Girard C, Bemelmans A-P, Dufour N, Mallet J, Bachelin C, Nait-Oumesmar B et al (2005). Grafts of brain-derived neurotrophic factor and neurotrophin 3-transduced primate Schwann cells lead to functional recovery of the demyelinated mouse spinal cord. J Neurosci 25: 7924-7933.
47. Graca DL, Blakemore WF (1986). Delkayed remyelination in the rat spinal cord following ethidium bromide injection. Neuropathol Appl Neurobiol 12: 593-605.
48. Gregg C, Shikar V, Larsen P, Mak G, Chojnacki A, Yong VW et al (2007). White matter plasticity and enhanced remyelination in the maternal CNS. J Neurosci 27: 1812-1823.
49. Grinspan J, Wrabetz L, Kamholz J (1993). Oligodendrocyte maturation and myelin gene expression in PDGF-treated cultures from rat cerebral white matter. J Neurocytol 22: 322-333.
50. Guazzo EP (2005). A technique for producing demyelination of the rat optic nerves. J Clin Neurosci 12: 54-58.
51. Honmou O, Felts PA, Waxman SG, Kocsis JD (1996). Restoration of normal conduction properties in demyelinated spinal cord axons in the adult rat by transplantation of exogenous Schwann cells. J Neurosci 16: 3199-3208.
52. Honnegger P (1985). Biochemical differentiation in serum-free aggregating brain cell cultures. In: Bottenstein JE, Sato G (eds). Cell Culture in Neurosciences. Plenum: New York. pp 223-243.
53. Hunter MIS, Nlemadim BC, Davidson DLW (1985). Lipid peroxidation production and antioxidant proteins in plasma and cerebrospinal fluid from multiple sclerosis patients. Neurochem Res 10: 1645-1652.
54. Husain J, Juurlink BHJ (1995). Oligodendroglial precursor cell susceptibility to hypoxia is related to poor ability to cope with reactive oxygen species. Brain Res 698: 86-94.
55. Ibanez C, Shields SA, El-Etr M, Baulieu E-E, Schumacher M, Franklin RJM (2004). Systemic progesterone administration results in a partial reversal of the age-associated decline in CNS remyelination following toxin-induced demyelination in rats. Neuropathol Appl Neurobiol 30: 80-89.
56. Irvine K-A, Blakemore WF (2006). Age increases axon loss associated with primary demyelination in cuprizone-induced demyelination in C57Bl/6 mice. J Neuroimmunol 175: 69-76.
57. Ishibashi T, Dakin KA, Stevens B, Lee PR, Kozlov SV, Stewart CL et al (2006). Astrocytes promote myelination in response to electrical impulses. Neuron 49: 823-832.
58. Issazadeh S, Lorentzen JC, Mustafa MI, Hojeberg B, Mussener A, Olsson T (1996). Cytokines in relspaing experimental autoimmune encephalomyelitis in DA rats: persistent mRNA expression of proinflammatory cytokines and absent expression of interleukin-10 and transforming growth factor-β. J Neuroimmunol 69: 103-115.
59. Jaillard C, Harrison S, Stankoff B, Aigrot MS, Calver AR, Duddy G et al (2005). Edg9/S1P5: an oligodendoglial receptor with dual function on process retraction and cell survival. J Neurosci 25: 1459-1469.
60. James T, Matzelle D, Bartus R, Hogan EL, Banik NL (1998). New inhibitors of calpain prevent degradation of cytoskeletal and myelin proteins in spinal cord in vitro. J Neurosci Res 51: 218-222.
61. Jeffrey ND, Blakemore WF (1995). remyelination of mouse spinal cord axons demyelinated by local injection of lysolecithin. J Neurocytol 24: 775-781.
62. Jensen NA, Smith GM, Garvey JS, Shine HD, Hood L (1993). Cyclic AMP has a differentiative effect on an immortalized oligodendrocyte cell line. J Neurosci Res 35: 288-296.
63. Johnson AW, Land JM, Thompson EJ, Bolanos JP, Clark JB, Heales SJR (1995). Evidence for increased nitric oxide production in multiple sclerosis. Letter. J Neurol Neurosurg Psychiatry 58: 107.
64. Jordan CA, Friedrich Jr VL, de Ferra F, Weismiller DG, Holmes KV, Dubois-Dalcq M (1990). Differential exon expression in myelin basic protein transcripts during central nervous system (CNS) remyelination. Cell Mol Neurobiol 10: 3-18.
65. Kanwar JR, Kanwar RK, Krissansen GW (2004). Simultaneous neuroprotection and blockade of inflammation reverses autoimmune encephalomyelitis. Brain 127: 1313-1331.
66. Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, et al, FTY720 D2201 Study Group (2006). Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Eng J Med 355: 1124-1140.
67. Kashima T, Tiu SN, Merrill JE, Vinters HV, Dawson G, Campagnoni AT (1993). Expression of oligodendrocyte-associated genes in cell lines derived from human gliomas and neuroblastomas. Cancer Res 53: 170-175.
68. Keirstead HS, Levine JM, Blakemore WF (1998). Response of the oligodendrocyte progenitor cell population (defined by NG2 labelling) to demyelination of the adult spinal cord. Glia 22: 161-170.
69. Knutson P, Ghiani CA, Zhou JM, Gallo V, McNain CJ (1997). K+ channel expression and cell proliferation are regulated by intracellular sodium and membrane depolarization in oligodendrocyte progenitor cells. J Neurosci 17: 2669-2682.
70. Kotter MR, Setzu A, Sim FJ, Van Rooijen N, Franklin RJM (2001). Macrophage depletion impairs oligodendrocyte remyelination following lysolecithin-induced demyelination. Glia 35: 204-212.
71. AB) promote adult SVZ-derived oligodendrogenesis in vivo. Mol Cell Neurosci 20: 390-403.
72. Lalive PH, Menge T, Delarasse C, Della Gaspera B, Pham-Dinh D, Villoslada P et al (2006). Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. Proc Natl Acad Sci USA 103: 2280-2285.
73. Larocca JN, Farooq M, Norton WT (1997). Induction of oligodendrocyte apoptosis by C2-ceramide. Neurochem Res 22: 529-534.
74. Lassmann H, Bruck W, Lucchinetti C, Rodriguez M (1997). Remyelination in multiple sclerosis. Mult Scler 3: 133-136.
75. Lorentzen JC, Issazadeh S, Storch M, Mustafa MI, Lassmann H, Linington C et al (1995). Protracted, relapsing and dmyelinating experimental autoimmune encephalomyelitis in DA rats immunized with syngeneic spinal cord and incomplete Freund's adjuvant. J Neuroimmunol 63: 193-205.
76. Loughlin AJ, Copelman CA, Hall A, Armer T, Young BC, Landon DN et al (1997). Myelination and remyelination of aggregate rat brain cultures enriched with macrophages. J Neurosci Res 47: 384-392.
77. Louis JC, Magal E, Muir D, Manthorpe M, Varon S (1992). CG-4, a new bipotential glial cell line from rat brain, is capable of differentiating in vitro into either mature oligodendrocytes or type-2 astrocytes. J Neurosci Res 31: 193-204.
78. Lubetzki C, Demerens C, Anglade P, Villarroya H, Frankfurter A, Lee VM-Y (1993). Even in culture, oligodendrocytes myelinate solely axons. Proc Natl Acad Sci USA 90: 6820-6824.
79. Ludwin SK (1978). Central nervous system demyelination and remyelination in the mouse: an ultrastructural study of cuprizone toxicity. Lab Invest 39: 597-612.
80. MacKenzie-Graham AJ, Mitrovic B, Smoll A, Merrill JE (1994). Differential sensitivity to nitric oxide in immortalized, cloned murine oligodendrocyte cell lines. Dev Neurosci 16: 162-171.
81. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J et al (2002). Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296: 346-349.
82. Marmur R, Kessler JA, Zhu G, Gokhan S, Mehler MF (1998). Differentiation of oligodendroglial progenitors derived from cortical multipotent cells requires extrinsic signals including activation of gp130/LIFβ receptors. J Neurosci 18: 9800-9811.
83. Martel RP, Botros IW, Rounseville MP, Hinton JP, Staples RR, Morales DA et al (2002). Multiplexed screening assay for mRNA combining nuclease protection with luminescent array detection. Assay Drug Dev Technol 1: 61-71.
84. Mason JL, Suzuki K, Chaplin DD, Matsushima GK (2001). Interleukin-1β promotes repair of the CNS. J Neurosci 21: 7046-7052.
85. Mason JL, Toews A, Hostettler JD, Morell P, Suzuki K, Goldman JE et al (2004). Oligodendrocytes and progenitors become progressively depleted within chronically demyelinated lesions. Am J Pathol 164: 1673-1682.
86. Mason JL, Ye P, Suzuki K, D'Ercole AJ, Matsushima GK (2000). Insulin-like growth factor-1 inhibits mature oligodendrocyte apoptosis during primary demyelination. J Neurosci 20: 5703-5708.
87. Matsushima GK, Morell P (2001). The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol 11: 107-116.
88. Matute C, Alberdi W, Domercq M, Perez-Cerda F, Perez-Samartin A, Sanchez-Gomez MV (2001). The link between excitotoxic oliogodendroglial death and demyelinating diseases. Trends Neurosci 24: 224-230.
89. McCarthy M, deVellis J (1980). preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissues. J Cell Biol 85: 890-902.
90. Merkler D, Boretius S, Stadelmann C, Ernsting T, Michaelis T, Frahm J et al (2005). Multicontrast MRI of remyelination in the central nervous system. NMR Biomed 18: 395-403.
91. Merrill JE, Ignarro LJ, Sherman MP, Melinek J, Lane TE (1993). Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J Immunol 15: 2123-2141.
92. Merrill JE, Matsushima K (1988). Production and response to interleukin 1 by cloned human oligodendroglioma cell lines. J Biol Regul Homeo Agents 2: 77-86.
93. Merrill JE, Scolding NJ (1999). Mechanisms of damage to myelin and oligodendrocytes and their relevance to disease. Neuropathol Appl Neurobiol 25: 435-458.
94. Mi S, Hu B, Hahm K, Luo Y, Hui ESK, Yuan Q et al (2007). LINGO-1 antagonist promotes spinal cord remyelimation and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat Med 13: 1228-1233.
95. Miron VE, Jung CG, Kim HJ, Kennedy TE, Soliven B, Antel JP (2008). FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol 63: 61-71.
96. Miron VE, Rajasekharan S, Jarjour AA, Zamvil SS, Kennedy TE, Antel JP (2007). Simvastatin regulates oligodendroglial process dynamics and survival. Glia 55: 130-143.
97. Mitrovic B, Ignarro LJ, Montestruque S, Smoll A, Merrill JE (1994). Nitric oxide as a potential pathological mechanism in demyelination: its differential effects on primary glial cells in vitro. Neuroscience 61: 575-585.
98. Mitrovic B, Ignarro LJ, Vinters HV, Akers M-A, Schmid I, Uittenbogaart C et al (1995). Nitric oxide induces necrotic but not apoptotic cell death in oligodendrocytes. Neuroscience 65: 531-539.
99. Mitrovic B, Parkinson J, Merrill JE (1996). An in vitro model of oligodendrocyte destruction by nitric oxide and its relevance to multiple sclerosis. Methods: Comp Methods Enzymol 10: 501-513.
100. Murray K, Dubois-Dalcq M (1997). Emergence of oligodendrocytes from human neural spheres. J Neurosci Res 50: 146-156.
101. Nicolay DJ, Doucette JR, Nazarali AJ (2007). Transcriptional control of oligodendrogenesis. Glia 55: 1287-1299.
102. Nunes MC, Roy NS, Keyoung HM, Goodman RR, McKhann II G, Jiang L et al (2003). Identification and isolation of multipotential neural progenitor cells from the subcortical white matter of the adult human brain. Nat Med 9: 439-447.
103. O'Connor PW, Li D, Freedman MS, Bar-Or A, Rice GPA, Confavreux C et al (2006). A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 66: 894-900.
104. Offner H (2004). Neuroimmunoprotective effects of estrogen and derivatives in experimental autoimmune encephalomyelitis: therapeutic implications for multiple sclerosis. J Neurosci Res 78: 603-624.
105. Ohori Y, Tamamoto S-I, Nagao M, Sugimori M, Yamamoto N, Nakamura K et al (2006). Growth factor treatment and genetic manipulation stimulate neurogenesis and oligodendrogenesis by endogenous neural progenitors in the injured adult spinal cord. J Neurosci 26: 11948-11960.
106. Okano H, Sakaguchi M, Ohki K, Suzuki N, Sawamoto K (2007). Regeneration of the central nervous system using endogenous repair mechanisms. J Neurochem 102: 1459-1465.
107. Otero GC, Merrill JE (1997). Response of human oligodendrocytes to interleukin-2. Brain Behav Immun 11: 24-38.
108. Oudega M, Xu XM, Guenard V, Kleitman N, Bunge MB (1997). A combination of insulin-like growth factor-I and platelet-derived growth factor enhances myelination but diminishes axonal regeneration into Schwann cell grafts in the adult rat spinal cord. Glia 19: 247-258.
109. Patneau DK, Wright PW, Winters C, Mayer ML, Callo V (1994). Glial cells of the oligodendrocyte lineage express both kainate- and AMPA-preferring subtypes of glutamate receptor. Neuron 12: 357-371.
110. Pfeiffer SE, Warrington AE, Bansal R (1993). The oligodendrocyte and it many processes. Trends Cell Biol 3: 191-197.
111. Pluchino S, Quattrini A, Brambilla E, Gritti A, Salani G, Dina G et al (2003). Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature 422: 688-694.
112. Prineas JW (1985). The neuropathology of multiple sclerosis. In: Vincken PJ, Bruyn GW, Klawans HL (eds). Demyelinating Diseases. Elsevier Science: Amsterdam, pp 213-257.
113. Prineas JW, Barnard RO, Kwon EE, Sharer LR, Cho E-S (1993). Multiple sclerosis: remyelination of nascent lesions. Ann Neurol 33: 137-151.
114. Prineas JW, Connell F (1979). Remyelination in multiple sclerosis. Ann Neurol 5: 22-31.
115. Prineas JW, Kwon EE, Cho E-S, Sharer LR (1984). Continual breakdown and regeneration of myelin in progressive multiple sclerosis. Ann NY Acad Sci 436: 11-32.
116. Prineas JW, Kwon EE, Goldenberg PZ, Ilyas AA, Quarles RH, Benjamins JA et al (1989). Multiple sclerosis: oligodendrocyte proliferation and differentiation in fresh lesions. Lab Invest 61: 489-503.
117. Raible DW, McMorris FA (1989). Cyclic AMP regulates the rate of differentiation of oligodendrocytes without changing the lineage commitment of their progenitors. Dev Biol 133: 437-446.
118. Raine CS (1997). The Norton Lecture: a review of the oligodendrocyte in the multiple sclerosis lesion. J Neuroimmunol 77: 135-152.
119. Raine CS, Barnett LB, Brown A, Behar T, McFarlin DE (1980). Neuropathology of experimental allergic encephalomyelitis in inbred strains of mice. Lab Invest 43: 150-157.
120. Raine CS, Wu E (1993). Multiple sclerosis: remyelination in acute lesions. J Neuropathol Exp Neurol 52: 199-204.
121. Roy NS, Wang S, Harrison-Restelli C, benraiss A, Fraser FA, Gravel M et al (1999). Identification, isolation, and promoter-defined separation of mitotic oligodendrocyte progenitor cells from the adult human subcortical white matter. J Neurosci 19: 9986-9995.
122. Saxe JP, Wu H, Kelly TK, Phelps ME, Sun YE, Kornblum HI et al (2007). A phenotypic small-molecule screen identifies an orphan ligand-receptor pair that regulates neural stem cell differentiation. Chem Biol 14: 1019-1030.
123. Scolding NJ, Compston DA (1995). Growth factors fail to protect rat oligodendrocytes against humoral injury in vitro. Neurosci Lett 183: 75-78.
124. Selmaj K, Brosnan CF, Raine CS (1991). Colocalization of lymphocytes bearing gamma delta T-cell receptor and heat shock protein hsp65+ oligodendrocytes in multiple sclerosis. Proc Natl Acad Sci USA 88: 6452-6456.
125. Selmaj K, Brosnan CF, Raine CS (1992). Expression of heat shock protein-65 by oligodendrocytes in vivo and in vitro: implications for multiple sclerosis. Neurology 42: 795-800.
126. Sergott RC, Brown MJ, Silberberg DH (1985). Remyelination follows antibody-induced central nervous system demyelination. Ann Neurol 20: 94-98.
127. Sim FJ, Lang JK, Waldau B, Roy NS, Schwartz TE et al (2006). Complementary patterns of gene expression by human oligodendrocyte progenitors and their environment predict determinants of progenitor maintenance and differentiation. Ann Neurol 59: 763-779.
128. Sim FJ, Zhao C, Penderis J, Franklin RJM (2002). The age-related decrease in CNS remyelination efficiency is attributable to an impairment of both oligodendrocyte progenitor recruitment and differentiation. J Neurosci 22: 2451-2459.
129. Smorodchenko A, Wuerfel J, pohl EE, Vogt J, Tysiak E, Glumm R et al (2007). CNS-irrelevant T-cells enter the brain, cause blood-brain barrier disruption but no glial pathology. Eur J Neurosci 26: 1387-1398.
130. Sperber BR, McMorris FA (2001). Fyn tyrosine kinase regulates oligodendroglial cell development but is not required for morphological differentiation of oligodendrocytes. J Neurosci Res 63: 303-312.
131. Stangel M (2004). Remyelinating and neuroprotective treatments in multiple sclerosis. Expert Opin Investig Drugs 13: 331-347.
132. Stevens B, Porta S, Haak LL, Gallo V, Fields RD (2002). Adenosine: a neuron-glial transmitter promoting myelination in the CNS in response to action potentials. Neuron 36: 855-868.
133. Takao T, Flint N, Lee L, Ying X, Merrill J, Chandross KJ (2004). 17beta-estradiol protects oligodendrocytes from cytotoxicity induced cell death. J Neurochem 89: 660-673.
134. Tanaka K, Nogawa S, Suzuki S, Dembo T, Kosakai A (2003). Upregulation of oligodendrocyte progenitor cells associated with restoration of mature oligodendrocytes and myelination in peri-infarct area in the rat brain. Brain Res 989: 172-179.
135. Thorburne SK, Juurlink BHJ (1996). Low glutathione and high iron govern the susceptibility of oligodendroglial precursors to oxidative stress. J Neurochem 67: 1014-1022.
136. Tiwari-Woodruff S, Morales LBJ, Voskuhl RR (2007). Differential neuroprotective and anti-inflammatory effects of estrogen receptor (ERα and ERβ) ligand treatment. Proc Natl Acad Sci USA 104: 14813-14818.
137. Toman RE, Payne SG, Watterson KR, Maceyka M, Lee NH, Milstein S et al (2004). Differential activation of sphingosine-1-phosphate receptors modulates NGF-induced neurite extension. J Cell Biol 166: 381-392.
138. Tosic M, Torch S, Comte V, Dolivo M, Honegger P, Matthieu J-M (1992). Triiodothyronine has diverse and multiple stimulating effects on expression of the major myelin protein genes. J Neurochem 59: 1770-1777.
139. Touil T, Deloire-Grassin MS, Vital C, Petry KG, Brochet B (2001). In vivo damage of CNS myelin and axons induced by peroxynitrite. Neuroreport 12: 3637-3644.
140. Vartanian T, Li Y, Zhao M, Stefansson K (1995). Interferon-gamma-induced oligodendrocyte cell death: implications for the pathogenesis of multiple sclerosis. Mol Med 1: 732-743.
141. Verity AN, Bredesen D, Vonderscher C, Handley VW, Campagnoni AT (1993). Expression of myelin protein genes and myelin components in an oligodendrocyte cell line conditionally immortalized with a temperature sensitive retrovirus. J Neurochem 60: 577-587.
142. Wang C, Pralong WF, Schultz MF, Rougon G, Aubry JM, Pagliusi S et al (1996). Functional N-methyl-D-aspartate receptors in O-2A glial precursor cells: a critical role in regulating polysialic acid-neural cell adhesion molecule expression and cell migration. J Cell Biol 135: 1565-1581.
143. Webster HD (1997). Growth factors and myelin regeneration in multiple sclerosis. Mult Scler 3: 113-120.
144. Wilson HC, Onischke C, Raine CS (2003). Human oligodendrocyte precursor cells in vitro: phenotypic analysis and differential response to growth factors. Glia 44: 153-165.
145. Woodruff RH, Franklin RJM (1999). Demyelination and remyelination of the caudal cerebellar peduncle of adult rats following stereotaxic injections of lysolecithin, ethidium, bromide, and complement/anti-galactocerebroside. Glia 25: 216-228.
146. Wuerfel J, Tysiak E, Prozorovski T, Smyth M, Mueller S, Schnorr J et al (2007). Mouse model mimics multiple sclerosis in the clinico-radiological paradox. Eur J Neurosci 26: 190-198.
147. Yang H, Lu P, McKay HM, Bernot T, Keirstead H, Steward O et al (2006). endogenous neurogenesis replaces oligodendrocytes and astrocytes after primate spinal cord injury. J Neurosci 26: 2157-2166.
148. Yoshioka A, Hardy M, Younkin DP, Grinspan JB, Stern JL, Pleasure D (1995). Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors mediate excitotoxicity in the oligodendroglial lineage. J Neurochem 64: 2442-2448.
149. Yoshioka A, Shimizu Y, Hirose G, Kitasato H, Pleasure D (1998). Cyclic AMP-elevating agents prevent oligodendroglial excitotoxicity. J Neurochem 70: 2416-2423.
150. Zhang Y, Taveggia C, Melendez-Vasquez C, Einheber S, Raine CS, Salzer JL et al (2006). Interleukin-11 potentiates oligodendrocyte survival and maturation, and myelin formation. J Neurosci 26: 12174-12185.
151. Zhang Z, Cerghet M, Mullins C, Williamson M, Bessert D, Skoff R (2004). Comparison of in vivo and in vitro subcellular localization of estrogen receptors α and β in oligodendrocytes. J Neurochem 89: 674-684.